Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 3:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 529 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Omega-3 fatty acid Clear all
Completed No phase listed Observational Accepts healthy volunteers

Plasma Neurofilament Light and Its Relationship With Omega-3 Status and Soccer Heading in Women Soccer Players

NCT05457023
View directory record Official record
Conditions
Brain Trauma
Interventions
Plasma Neurofilament Light (NF-L), Omega-3 Index, HeadCount Questionnaire
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 17, 2026, 3:35 PM EDT
Not listed Early Phase 1 Interventional

Lovaza's Effect on Clopidogrel in a Neuro Population

NCT01526824
View directory record Official record
Conditions
Ischemic Stroke, Transient Ischemic Attack
Interventions
omega-3 polyunsaturated fatty acids (Lovaza)
Dietary Supplement
Lead sponsor
Millard Fillmore Gates Hospital
Other
Eligibility
25 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2012 · Synced Sep 17, 2026, 3:35 PM EDT
Completed Not applicable Interventional

The Triglyceride Lowering Effect of an Omega-3 Fat (DHA) in Addition to Statin Therapy for Patients With CAD or Diabetes

NCT00360217
View directory record Official record
Conditions
Hypertriglyceridemia (TG>200<500), Hyperlipidemia, Coronary Artery Disease, Coronary Risk Equivalent, Diabetes
Interventions
docosahexanoic acid (DHA)
Drug
Lead sponsor
Maine Center for Lipids and Cardiovascular Health
Other
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Scarborough, Maine
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Sep 17, 2026, 3:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Omega-3 Fatty Acids to Combat Sarcopenia

NCT02103842
View directory record Official record
Conditions
Sarcopenia
Interventions
Omega-3 fatty acids
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 17, 2026, 3:35 PM EDT
Completed Phase 1 Interventional Results available

NAPLS Omega-3 Fatty Acid Versus Placebo Study

NCT01429454
View directory record Official record
Conditions
Psychosis
Interventions
Omega-3 Long Chain Fatty Acid, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
12 Years to 30 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Sep 17, 2026, 3:35 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Epanova® for Lowering Very High Triglycerides

NCT01242527
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
placebo, omefas
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
30
States / cities
National City, California • Sacramento, California • Manchester, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Sep 17, 2026, 3:35 PM EDT
Completed Phase 2 Interventional

Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy

NCT00004448
View directory record Official record
Conditions
IgA Glomerulonephritis
Interventions
omega-3 fatty acids, prednisone, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Up to 40 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 17, 2026, 3:35 PM EDT
Terminated Phase 2 Interventional Results available

Vitamin D and n-3 Polyunsaturated Fatty Acids (PUFAs) to Prevent Chronic Pain Following Major Thermal Burn Injury

NCT03313076
View directory record Official record
Conditions
Chronic Pain Following Thermal Burn Injury
Interventions
Omega-3 fatty acids (fish oil), Vitamin D3 (cholecalciferol), Vitamin D3 (cholecalciferol) placebo, Omega-3 fatty acid placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 17, 2026, 3:35 PM EDT
Withdrawn Phase 4 Interventional

Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia

NCT01180764
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Lovaza (Omega-3 acid ethyl esters), Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
35 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 17, 2026, 3:35 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

NCT04006847
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Chronic Phase
Interventions
Eicosapentaenoic Acid, Tyrosine kinase inhibitor
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 17, 2026, 3:35 PM EDT
Completed Phase 2 Interventional Results available

Fatty Acid Supplementation in Children With ASD

NCT03550209
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
LCPUFA Oil Supplement, Canola Oil Placebo
Drug · Dietary Supplement
Lead sponsor
Sarah Keim
Other
Eligibility
2 Years to 6 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Sep 17, 2026, 3:35 PM EDT
Completed Not applicable Interventional

Omega-3 Supplementation for Smell Dysfunction

NCT02529332
View directory record Official record
Conditions
Sellar/Parasellar Tumor, Smell Dysfunction
Interventions
Omega-3
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Stanford, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Sep 17, 2026, 3:35 PM EDT
Completed Not applicable Interventional

Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye

NCT00883649
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Hydroeye, Inactive Capsule
Dietary Supplement · Other
Lead sponsor
Virginia Eye Consultants
Other
Eligibility
40 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
Houston, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2012 · Synced Sep 17, 2026, 3:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ranger Resilience and Improved Performance on Phospholipid Bound Omega-3's

NCT02908932
View directory record Official record
Conditions
Nutrition, Fatty Acids, Omega-3, Cognition, Resilience, Psychological, Psychology, Military
Interventions
Phospholipid-bound omega-3 supplement, Placebo supplement
Dietary Supplement
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Not listed
Enrollment
555 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
3
States / cities
Fort Benning, Georgia • Bethesda, Maryland • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 17, 2026, 3:35 PM EDT
Terminated Phase 2 Interventional Results available

OPTIMA-TBI Pilot Study

NCT03345550
View directory record Official record
Conditions
Mild Traumatic Brain Injury
Interventions
Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules., Placebo - Cap
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Sep 17, 2026, 3:35 PM EDT
Completed Phase 3 Interventional Results available

Effect of Omega-3 Fatty Acid on Cortical Function in ADHD

NCT01883817
View directory record Official record
Conditions
Attention Deficit Disorder
Interventions
DHA Omega-3, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
5 Years to 15 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 17, 2026, 3:35 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

NCT06195306
View directory record Official record
Conditions
Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Biospecimen Collection, Mammography, Omega-3-Acid Ethyl Esters, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
45 Years to 74 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Kansas City, Kansas • Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 17, 2026, 3:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolic Actions of Omega-3 Fatty Acids

NCT01896414
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
EPA (marine fatty acids), Placebo
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
25 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 17, 2026, 3:35 PM EDT
Completed Phase 2 Interventional Results available

Omega-3 Fatty Acids for Autism Treatment

NCT00786799
View directory record Official record
Conditions
Autism
Interventions
Omega-3 Fatty Acids
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Years to 8 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Sep 17, 2026, 3:35 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Omega-3D: Omega-3 for Diet-Driven Health Disparities

NCT07078344
View directory record Official record
Conditions
Heart Health Markers, Cardiovascular Diseases, Omega 3 Fatty Acids
Interventions
Omega-3 Fatty Acids and Safflower Oil Placebo, Safflower Oil Placebo and Omega-3 Fatty Acids
Dietary Supplement
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 64 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Tucson, Arizona • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 17, 2026, 3:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome

NCT00344721
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Omega-3 fatty acid supplement, Placebo
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced Sep 17, 2026, 3:35 PM EDT
Withdrawn No phase listed Observational

Omega-3 Fatty Acid Status in Morbid Obesity Before and After Surgical Treatment

NCT00558532
View directory record Official record
Conditions
Morbid Obesity, Cardiovascular Disease, Fatty Acid Levels
Interventions
Bariatric Surgery
Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Sep 17, 2026, 3:35 PM EDT
Not listed No phase listed Observational

Effects of Omega-3 Fatty Acids on Platelets in Patients With Coronary Artery Disease With Hypertriglyceridemia

NCT01086163
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Omacor, omega-3 fatty acids in CAD patients
Drug
Lead sponsor
HeartDrug Research LLC
Other
Eligibility
50 Years to 60 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2010 · Synced Sep 17, 2026, 3:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults

NCT02514070
View directory record Official record
Conditions
Lipoprotein Metabolism, PCSK9, Proteomics
Interventions
EPA-rich fish oil, DHA-rich fish oil
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Sep 17, 2026, 3:35 PM EDT